Your browser is no longer supported. Please, upgrade your browser.
ADAP Adaptimmune Therapeutics plc daily Stock Chart
ADAP [NASD]
Adaptimmune Therapeutics plc
Index- P/E- EPS (ttm)-1.27 Insider Own0.10% Shs Outstand123.29M Perf Week-14.65%
Market Cap1.21B Forward P/E- EPS next Y-0.96 Insider Trans-81.31% Shs Float31.76M Perf Month-14.29%
Income-137.90M PEG- EPS next Q-0.25 Inst Own70.10% Short Float11.82% Perf Quarter79.73%
Sales1.90M P/S638.90 EPS this Y-33.20% Inst Trans12.05% Short Ratio1.14 Perf Half Y95.59%
Book/sh1.51 P/B5.28 EPS next Y-16.80% ROA-60.30% Target Price12.83 Perf Year303.03%
Cash/sh1.29 P/C6.18 EPS next 5Y1.00% ROE-85.60% 52W Range0.71 - 13.40 Perf YTD565.00%
Dividend- P/FCF- EPS past 5Y-46.40% ROI-113.30% 52W High-40.45% Beta2.18
Dividend %- Quick Ratio7.60 Sales past 5Y-30.30% Gross Margin- 52W Low1025.53% ATR0.61
Employees400 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)33.94 Volatility6.35% 6.86%
OptionableYes Debt/Eq0.00 EPS Q/Q12.80% Profit Margin- Rel Volume0.27 Prev Close8.06
ShortableYes LT Debt/Eq0.00 EarningsAug 06 BMO Payout- Avg Volume3.29M Price7.98
Recom2.40 SMA20-10.97% SMA50-17.18% SMA20079.35% Volume875,534 Change-0.99%
Apr-22-20Initiated Mizuho Neutral $3
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
Mar-17-17Initiated Wells Fargo Market Perform
Oct-24-16Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16Initiated Raymond James Outperform $16
Feb-25-16Initiated Citigroup Buy $15
Jun-01-15Initiated Leerink Partners Outperform $24
Jun-01-15Initiated Guggenheim Buy
Jun-01-15Initiated BofA/Merrill Neutral
Aug-06-20 07:30AM  
Jul-23-20 04:00PM  
Jul-22-20 08:00AM  
Jul-05-20 02:25PM  
Jun-23-20 11:26AM  
Jun-17-20 09:33AM  
08:52AM  
Jun-12-20 06:30AM  
Jun-08-20 10:30AM  
Jun-04-20 10:45AM  
Jun-02-20 04:37AM  
12:38AM  
Jun-01-20 09:39PM  
12:51PM  
11:01AM  
09:38AM  
06:09AM  
06:00AM  
04:15AM  
May-29-20 05:08PM  
02:20PM  
10:32AM  
10:24AM  
07:30AM  
May-19-20 07:02AM  
May-14-20 12:00PM  
08:55AM  
07:30AM  
May-12-20 08:00AM  
06:07AM  
Apr-29-20 08:00AM  
Apr-28-20 12:00PM  
08:00AM  
Mar-20-20 10:40PM  
Mar-11-20 11:35AM  
Feb-29-20 08:31AM  
Feb-27-20 07:30AM  
06:00AM  
Feb-24-20 03:15PM  
Feb-20-20 04:00PM  
Feb-18-20 08:00AM  
Feb-07-20 04:05PM  
Feb-05-20 11:30AM  
Feb-03-20 09:13AM  
Jan-24-20 04:30PM  
Jan-22-20 01:18PM  
08:48AM  
08:25AM  
06:48AM  
Jan-21-20 04:08PM  
Jan-17-20 12:00PM  
Jan-15-20 08:22AM  
Jan-14-20 12:29PM  
07:55AM  
02:08AM  
Jan-13-20 08:30AM  
02:00AM  
Dec-30-19 05:25AM  
Dec-16-19 05:45AM  
Dec-03-19 02:20PM  
08:30AM  
Nov-17-19 11:40AM  
Nov-16-19 02:00AM  
Nov-06-19 07:30AM  
Nov-01-19 08:00AM  
Oct-31-19 01:52PM  
06:09AM  
Oct-09-19 08:00AM  
Oct-01-19 08:00AM  
Sep-30-19 08:45AM  
Sep-16-19 06:41AM  
Sep-10-19 09:01AM  
Sep-09-19 08:00AM  
Aug-27-19 02:11PM  
08:00AM  
Aug-16-19 11:23AM  
Aug-01-19 10:24PM  
07:15AM  
07:15AM  
Jul-29-19 04:05PM  
Jul-25-19 08:00AM  
Jul-22-19 08:00AM  
Jul-18-19 11:00AM  
08:00AM  
Jul-09-19 11:23AM  
09:00AM  
Jun-29-19 05:37PM  
Jun-27-19 02:54PM  
08:00AM  
May-28-19 10:14AM  
May-15-19 12:28PM  
08:00AM  
May-06-19 07:30AM  
07:00AM  
May-02-19 07:00AM  
May-01-19 08:00AM  
Apr-18-19 04:01PM  
Apr-12-19 03:26PM  
Apr-02-19 08:00AM  
Apr-01-19 08:00AM  
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TAYTON-MARTIN HELEN KATRINAChief Business OfficerAug 03Sale8.74200,0001,748,1800Aug 04 09:02 PM
Lunger JohnChief Patient Supply OfficerAug 03Sale9.254,82344,6138,066Aug 04 09:02 PM
Rawcliffe AdrianChief Executive OfficerAug 03Sale9.252,78825,7893,064Aug 04 09:01 PM
Wood GavinChief Financial OfficerJun 29Buy1.6233,00053,46033,000Jun 30 09:01 PM
Alleva Lawrence MDirectorJun 09Buy1.8912,90024,38112,900Jun 11 09:00 PM
Noble JamesDirectorMay 29Sale9.33500,0004,666,0000Jun 02 09:30 PM
Sonsini Peter W.10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:55 PM
SANDELL SCOTT D10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:54 PM
Florence Anthony A. Jr.10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:52 PM
MOTT DAVID MDirectorJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:53 PM
BASKETT FOREST10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:51 PM
Behbahani AliDirectorJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:52 PM
Bertrand William C JRChief Operating OfficerJan 14Sale5.132,39712,3083,605Jan 15 08:03 PM
Rawcliffe AdrianChief Executive OfficerJan 14Sale5.133,23616,6163,166Jan 15 08:01 PM
Lunger JohnChief Patient Supply OfficerJan 14Sale5.131,1445,8741,681Jan 15 08:02 PM
Norry ElliotChief Medical OfficerJan 14Sale5.139114,6781,326Jan 15 08:03 PM
TAYTON-MARTIN HELEN KATRINAChief Business OfficerJan 13Sale4.50100,000450,0000Jan 15 08:02 PM
Noble JamesDirectorJan 13Sale4.67300,0001,400,0000Jan 15 08:01 PM
Rawcliffe AdrianChief Executive OfficerJan 06Sale1.205,9007,0805,804Jan 07 08:00 PM
Bertrand William C JRChief Operating OfficerJan 06Sale1.203,7314,4775,632Jan 07 08:01 PM
Lunger JohnChief Patient Supply OfficerJan 06Sale1.201,1481,3781,677Jan 07 08:01 PM